Division of Cancer Prevention

Could a Vaccine Prevent Colorectal Cancer in People with Lynch Syndrome?

Researchers have taken the first steps toward developing a vaccine to prevent cancer in people with Lynch syndrome, an inherited condition that elevates a person’s risk of colorectal, endometrial, and other types of cancer.

The scientists, led by Steven Lipkin, MD, PhD, of Weill Cornell Medicine, reported results from NCI-funded tests of a cancer prevention vaccine at a recent meeting. The vaccine prevented the growth of colorectal tumors in a mouse model of Lynch syndrome and prolonged the mice’s survival compared with unvaccinated mice.

Read the NCI Cancer Currents Blog post

NCORP Tissue Procurement Protocol to Open at 12 Community Sites

At 12 NCI Community Oncology Research Program (NCORP) sites across the United States, a new kind of study will soon be opening for patients with advanced malignancies being treated with molecularly targeted therapies. The NCORP Tissue Procurement Protocol (NCI 10231, NCT 03707574) is not a treatment trial, but a study to assess if researchers can obtain tissue and blood samples at baseline and upon progression in patients with advanced cancer being treated with molecularly targeted therapies.

Read the NCI DCP News Note

PREVENT Cancer Preclinical Drug Development Program (PREVENT)

PREVENT supports development of the best ideas in cancer prevention intervention and biomarkers using NCI contract resources instead of direct funding. The program is a peer-reviewed pipeline that focuses on research needs that are not adequately addressed by the private sector.

Read more About PREVENT